Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276930 | 0.91 | ALDH1A1 (0.63) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL11423478 | 0.86 | ALDH1A1 (0.63) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL11833504 | 0.85 | ALDH1A1 (0.57) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL5458866 | 0.84 | ALDH1A1 (0.61) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL1285989 | 0.83 | ALDH1A1 (0.59) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL8392587 | 0.83 | ALDH1A1 (0.59) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL11757993 | 0.83 | ALDH1A1 (0.59) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| SCHEMBL145553 | 0.83 | ALDH1A1 (0.59) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| Ammonia Solution, Strong SCHEMBL11521448 | 0.81 | ALDH1A1 (0.57) | ALDH1A1GLATSHRL3MBTL1MEN1 | |
| Zinc Ion SCHEMBL5458862 | 0.81 | ALDH1A1 (0.57) | ALDH1A1GLATSHRL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2021-09-23 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-07-18 | — | — | US | disclosed |
| EP-1694748-B1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M INNOVATIVE PROPERTIES CO (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7273531-B2 | Method of modifying a fluoropolymeric substrate and composite articles thereby | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1694748-A1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M Innovative Properties Company (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005047373-A1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050092429-A1 | Method of modifying a fluoropolymeric substrate and composite articles thereby | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | ALDH1A1 1277/4885GLA 3772/4885TSHR 2223/4885 |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | ALDH1A1 2699/4885GLA 3755/4885TSHR 694/4885 |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | HIF1A, HIF1AN, UPF1 | ALDH1A1 1277/4885GLA 3772/4885TSHR 2223/4885 |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SCN9A, SCN7A, SCN8A | ALDH1A1 3949/4885GLA 4409/4885TSHR 2571/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | ALDH1A1 3390/4885GLA 4621/4885TSHR 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.